Cofactor Genomics

Cofactor Genomics is a biotechnology company that specializes in predictive immune modeling and RNA sequencing. By advancing precision medicine, Cofactor aims to address existing barriers in the healthcare sector, transitioning from single-analyte biomarkers to comprehensive multidimensional biomarkers through health expression models. The company operates one of the first CAP-certified clinical RNA sequencing laboratories, which enhances the efficiency and cost-effectiveness of clinical trials for their partners. Cofactor’s expertise encompasses molecular biology, informatics, and database management, allowing them to provide high-quality services tailored to the needs of the healthcare and pharmaceutical industries. Their focus on RNA biomarkers associated with responses to targeted therapeutics supports the commercialization of clinical diagnostic assays for oncologic, immunologic, and neurodegenerative diseases, ultimately contributing to medical research and improved patient outcomes.

David Messina Ph.D

Co-Founder and COO

1 past transactions

Narus Biotechnologies

Acquisition in 2016
Narus Biotechnologies, founded in 2015 by Raman Talwar and Ryan Bloom, is a U.S.-based company that specializes in the development of novel molecular diagnostics for cancer and neurological diseases. The company utilizes cell-free RNA technology to monitor neurodegeneration and offers biomarker development services. In February 2016, Narus Biotechnologies was acquired by Cofactor Genomics, further advancing its mission to address critical health challenges in the fields of neurology and oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.